A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
PMV Pharmaceuticals, Inc
Mayo Clinic
Sutro Biopharma, Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Tizona Therapeutics, Inc
IDEAYA Biosciences
Eli Lilly and Company
Seagen Inc.
Sairopa B.V.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tempest Therapeutics
Merck Sharp & Dohme LLC
NuCana plc
Medicenna Therapeutics, Inc.
Carisma Therapeutics Inc
NextCure, Inc.
Vincerx Pharma, Inc.
Pliant Therapeutics, Inc.
Corvus Pharmaceuticals, Inc.
Xencor, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Incyte Corporation
Silverback Therapeutics
Incyte Corporation
Incyte Corporation
Incyte Corporation